JG
AUPH icon

Jefferies Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Jefferies Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,550
Closed -$70.3K – 1528
2021
Q4 		$104K Buy
4,550
+4,450
+4,450% +$105K ﹤0.01% 1471
2021
Q3 		$2.21K Buy
+100
New +$1.59K ﹤0.01% 1670
2020
Q1 		– Sell
-6,000
Closed -$106K – 2050
2019
Q4 		$122K Buy
+6,000
New +$55.3K ﹤0.01% 2356

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Jefferies Group's AUPH Position: Q1 2022 in Review

Jefferies Group sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 4,550 shares — an estimated $70.3K sold.

Jefferies Group first reported a position in AUPH in Q4 2019 and held it in 3 quarters. The position peaked at $122K in Q4 2019. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • Jefferies Group reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 4,550 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $70.3K.
  • Jefferies Group first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Jefferies Group's Aurinia Pharmaceuticals position peaked at $122K in Q4 2019.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.